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ABSTRACT 
Objective 
Meta-analyses of trials of psychological treatments for emotional distress in breast cancer (BCa) conclude that efficacious treatments exist. 
Subsequently, their implementation in routine care is widely promoted by health policy. However, the methodological quality of these trials has 
not been systematically evaluated. The present review investigates this issue.   
Method 
A systematic search identified randomised controlled trials of psychological treatments for emotional distress in BCa. The Psychotherapy 
Outcome Study Methodology Rating Form was used to assess the quality of trials. Generic design elements, including representativeness of 
sample, control of concomitant treatments, reporting clinical significance outcomes, and design elements specific to psychotherapy trials, 
including manualisation, therapist training, and therapist adherence and competence were evaluated. 
Results 
91 trials were eligible. Overall, methodological quality was low. Generic design elements were limited in most trials: 15% specified as an 
inclusion criterion that participants were distressed; 10% controlled for concomitant treatments; and 11% reported the clinical significance of 
findings. Design elements specific to psychotherapy trials were also implemented poorly: 51% used treatment manuals; 8% used certified trained 
therapists; and monitoring of adherence and competence occurred in 15% and 4%, respectively.  
Conclusion 
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The methodological quality of psychological treatment trials for emotional distress in BCa is improving.  However, if relevant health policies are 
to be adequately empirically informed, trials of greater methodological rigour are essential. Trials should include participants with clinical levels 
of distress, control for concomitant treatments and report the clinical significance of findings. Trialists must also consider the specific 
requirements of psychotherapy trials.  
 
Keywords: Breast Cancer; Emotional Distress; Methodological Quality; Psychological Treatments; Randomised Controlled Trials 
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INTRODUCTION 
Improvement in detection methods and advances in treatment have increased survival in breast cancer (BCa), with an estimated 3.5 million BCa 
survivors in the United States(1). Around half of all newly diagnosed BCa patients report clinical levels of anxiety and/or depression based on 
either diagnostic criteria or cut-off points reflecting caseness on self-report or clinician administered questionnaires(2-4). For most, distress 
naturally diminishes over time. However, some patients continue to experience distress. According to DSM III-R criteria(5), around 25% of 
patients experience clinical levels of anxiety and/or depression in each of the second, third, and fourth years, and 15% in the fifth year after 
diagnosis(3). Emotional distress in BCa reduces quality of life, limits daily functioning, increases economic burden on health care systems, and 
decreases adjuvant treatment compliance(6-9). 
Many randomised controlled trials (RCTs) have therefore examined the efficacy of psychological treatments for emotional distress in BCa across 
the disease trajectory (i.e. shortly after diagnosis, during treatment, and survivorship). Two Cochrane reviews and several additional meta-
analyses of RCTs evaluating the efficacy of psychological treatments compared to controls produce small to modest effect sizes, with most 
concluding that efficacious treatments exist(10-17). Health care policies in the United States, England, and Canada have therefore specified that 
psychological treatments should be available to BCa patients as part of their routine care.  However, the methodological quality of RCTs for BCa 
patients experiencing emotional distress have yet to be comprehensively evaluated.  In the present review, this limitation is addressed. 
It is widely recognised that poor quality trials often overestimate treatment effects(18-23). For example, meta-analysis report larger effect sizes in 
RCTs that do not use intention to treat analyses(21, 23-25), adequate randomization(21, 24), and blind outcome assessors(21, 26).Whilst many meta-
analyses highlight that poor quality RCTs overestimate treatment effects, an additional concern is that poor quality undermines the confidence in 
the conclusions that can be drawn from RCTs(27-29). For example, if concomitant treatments are not controlled for, it is difficult to determine the 
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impact of the specific intervention being assessed; if an RCT is underpowered, between group effects may be undetected; and if 
psychometrically valid outcome measures are not used, researchers cannot be confident that intended outcomes were measured. 
It is therefore crucial that the quality of trials of psychological treatments is known if policymakers and clinicians are to make informed 
decisions about the implementation of, and referral to, psychological treatments in clinical services.  Assessing the methodological quality of 
RCTs has been fundamental to advancing the scientific credibility and reporting standards of psychotherapy outcome trials in mental health 
settings(21, 27-29). For example, it appears that as the quality of psychotherapy trials for depression have improved, the magnitude of treatment 
effects have diminished(23, 30).  
In BCa, there have been two Cochrane reviews that assessed the risk of bias (RoB) of individual trials(10, 11)  using the Cochrane RoB tool(31) 
(random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, complete 
outcome data, and selective outcome reporting) and both found that, in most trials, the RoB was unknown.  In addition,  two meta-analyses(13, 14) 
assessed the risk of bias using the Jadad scale(32) (random sequence generation, blinding of participants and personnel, and complete outcome 
data). One reported that 87% of trials were of high quality(13) while the other reported that only 29% were of high quality(14). A further meta-
analysis(12) assessed two RoB elements (random sequence generation and complete outcome data) and two other design features (adequacy of 
sample size and control for patient demoralisation) essential to high quality RCTs and reported that 44% of trials were of high methodological 
quality. However, all five failed to assess many other generic design features that are equally essential to high quality RCTs (including clarity of 
sample description, representativeness of the sample, specificity of outcome measures, reliability and validity of outcome measures, nature  of 
control conditions, length of follow-up, control of concomitant treatments, statistical methods, and reporting of clinical significance). Available 
meta-analyses therefore provide only a partial assessment of trial quality in BCa. 
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Moreover, meta-analyses have largely disregarded design elements that are important specifically for psychotherapy trials. Conclusions drawn 
from RCTs that inadequately specify the nature of the intervention being evaluated are of limited value and also negate replication(33). Therefore, 
treatment manuals are crucial to standardising psychological treatment and to discriminating between alternative treatments. Furthermore, to be 
confident that treatment was carried out as designed, it should be delivered by certified therapists trained in the treatment being investigated(34, 
35), and treatment must be monitored for therapist adherence (faithfulness to the prescribed treatment) and competence (skilfulness with which 
the treatment is delivered)(36, 37). Ideally, treatment should be delivered by more than one therapist and therapists should be included as a random 
design factor in analysis to avoid confounding between therapist and treatment(28). Lastly, the conclusions that can be drawn from a 
psychotherapy trial depend on whether the duration and intensity of treatment conditions was matched. Only two meta-analyses in BCa reported 
on psychotherapy-specific design elements, and in a limited manner(11, 12): Naaman and colleagues(12) assessed treatment fidelity and 
manualisation, and Mustafa and colleagues(11) provided information on  therapist training. 
Available meta-analyses have therefore inadequately assessed the methodological quality of RCTs in BCa. To overcome the limitations of 
previous assessments of trial quality, we used the Psychotherapy Outcome Study Methodology Rating Form (POMRF), which was explicitly 
designed to assess both generic design elements and those specific to psychotherapy trials(38).  The POMRF has been used to assess the quality of 
psychological treatment trials for mental health populations in four reviews. The first examined the quality of cognitive behavioural therapy 
(CBT) trials for depression in children(39), the second examined the quality of CBT trials for obsessive compulsive disorder in adults(28), and the 
third examined the quality of acceptance and commitment therapy trials across a range of mental and physical health conditions(40). The final 
review, also across a range of mental and physical health conditions, compared the quality of CBT trials to those using third wave CBT 
approaches and found that the quality of CBT trials were more methodologically rigorous(38). 
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Considering the recent evolution of methodological standards in psychological treatment trials generally, our study had five aims: (1) evaluate 
the overall quality of RCTs of psychological treatments for emotional distress in BCa, considering both generic design elements and those 
specific to psychotherapy trials; (2) evaluate specific design elements that have previously been inadequately evaluated in meta-analyses or are 
poorly implemented in clinical trials; (3) assess the quality of RCTs in this population against the benchmark of RCTs in mental health 
populations; (4) assess whether the quality of RCTs differ depending on the type of treatment being tested; and (5) determine whether  
methodological quality has improved over time. 
METHOD  
This review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement(41). All 
analyses used SPSS version 22.0.0.1. 
Eligibility criteria 
Eligibility criteria are detailed according to the PICOS framework(41). 
Participants.  The participants of the studies included in the present review were exclusively adults aged 18 years or older with a histologically 
confirmed diagnosis of BCa. Participants across all stages of the BCa disease trajectory (i.e. shortly after diagnosis, during medical treatment, 
and survivorship) were included. 
Interventions. As the term “psychological treatment” is poorly defined in the literature(10), we used a generic definition: treatments using 
psychological or behavioural techniques not based solely on impersonal media (i.e. written or visual material distributed on-line or by electronic 
or printed media).  
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Controls. Either no treatment (usual care) or active (attention placebo) control conditions. Trials comparing two or more specific psychological 
treatments without the use of a control condition were also included.  
Outcomes. The primary and/or secondary outcome was emotional distress, defined as anxiety, depression, general mood, or global emotional 
distress. This definition was chosen to be as inclusive as possible as it matches the inclusion criteria used in previous meta-analyses(10-13, 15). 
Studies. Only RCTs published in English in a peer-reviewed journal.  
Search strategy 
PubMed, PsycINFO, Web of science, Scopus, PsycARTICLE, and AMED were searched from their inception until October 2016 using Medical 
Subject Headings (MeSH) terms and keywords to identify psychological treatment trials for emotional distress in BCa. Combinations of terms 
associated with psychological treatments, emotional distress, and BCa were used. An English language filter was also used. The final search 
strategy used for PubMed, which is available in Appendix Table A1 (see online), was adapted for each electronic database. To ensure a 
comprehensive search, reference lists and relevant meta-analyses were hand-searched for additional studies.  
Study selection  
First, titles and abstracts were screened by one reviewer (JT) to remove clearly irrelevant reports. Next, full-text of all potentially relevant papers 
was retrieved and assessed for inclusion by the same reviewer (JT).  Uncertainties were discussed with a second reviewer (PF). When a single 
trial was published more than once, we evaluated the report that most thoroughly presented the methods and findings. Therefore, each paper 
represented a unique trial.  
Data extraction 
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Data were extracted independently by two reviewers for all included trials using a specially-devised data extraction form (JT & CH). Data 
extracted from trials included year of publication; country of origin; number of participants randomly assigned to condition; mean age; tumour 
stage; treatment status; outcome measures; treatment type; treatment format; duration of treatment; number of sessions; and type of control 
condition. Disagreements were resolved by discussion. The data extraction form is available on request from the first author. 
Aim 1: Overall quality of trials  
Methodological quality was rated using the POMRF (see online, Appendix Table A2). It consists of 22 items, each scored 0 (poor), 1 (fair), or 2 
(good), producing a total score ranging from 0 to 44, with higher scores indicating greater quality. Three items relating to psychiatric diagnoses 
(items 2, 4, & 8), irrelevant to this review, were disregarded; therefore, in this study, the maximum possible score was 38.  
A minimum cut-off score to determine adequate methodological quality on the POMRF has not been established. However, a review(27) which 
used the Randomized Controlled Trial Psychotherapy Quality Rating Scale (RCT-PQRS)(42) to evaluate the quality of psychodynamic trials 
provided a suitable benchmark. In that review, a cut off score of at least 50% of the maximum possible score on the RCT-PQRS was used. Thus, 
in this review a total score of 19 out of 38 was chosen as the criterion for minimum adequate quality. To compare quality on generic and specific 
items, we allocated POMRF items to two subscales: “generic design elements” (Table 1: maximum possible score of 26) and “psychotherapy-
specific design elements” (Table 1: maximum possible score of 12).  To allow comparison between the two subscales, total subscale scores were 
transformed into percentages of the maximum possible.  
Each trial was rated independently by two reviewers (JT & CH). To determine consistency of quality scores between the reviewers, inter-rater 
reliability was assessed using the intra-class correlation coefficient (ICC) for total quality scores, and the weighted kappa statistic for individual 
item scores. The ICC for total quality scores was 0.95 (95% CI, 0.92-0.97) and kappa for individual items ranged from 0.73 to 0.93, with mean 
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0.8, indicating good inter-rater reliability. Following the assessment of inter-rater reliability, discrepancies in ratings were resolved through 
discussion and consensus between both reviewers (JT & CH).  
Aim 2: Quality of specific design elements 
We descriptively evaluated all design elements specific to psychotherapy trials (Table 1) and generic ones that were particularly poorly 
implemented (i.e. a score of zero in at least 75% of trials). 
Table 1 
Subscale 1:  Generic design elements 
(maximum possible score of 26) 
Subscale 2: Psychotherapy-specific design elements 
(maximum possible score of 12) 
1. Clarity of sample description 13. Manualised, replicable, specific treatment programs 
3. Representativeness of sample 14. Number of therapists 
5. Specificity of outcome measures 15. Therapist training/experience 
6. Reliability and validity of outcome measures 16. Checks for treatment adherence 
7. Use of blind evaluators 17. Checks for therapist competence 
9. Assignment to treatment 22. Equality of therapy hours  
10. Design 
 
11. Power analysis 
 
12. Assessment points 
 
18. Control of concomitant treatments  
 
19. Handling of attrition 
 
20. Statistical analyses and presentation of results 
 
21. Clinical significance 
 
[Table 1. Items in the Psychotherapy outcome study methodology rating form] 
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Aim 3: Quality comparison with mental health populations 
To locate meta-analyses and systematic reviews evaluating the quality of RCTs using the POMRF in mental health populations, all papers citing 
the study in which the POMRF was devised were identified by searching Google Scholar. Potentially relevant papers were retrieved and 
assessed for eligibility. To compare the quality of RCTs in BCa with RCTs in mental health populations, for which the full 22-item scale was 
reported, scores were transformed into percentages of the maximum possible score on the scale, as well as on the two subscales. 
Aim 4: Quality comparison by treatment type 
Trials were stratified according to type of psychological treatment, grouped in five categories:  
Cognitive-behavioural based treatments were defined as those targeting specific thoughts or behaviours using cognitive, behavioural, or 
cognitive behavioural techniques. Procedures included cognitive restructuring, relaxation training, behavioural activation, and problem solving. 
Mindfulness based treatments were those focusing on guided meditation, visualisation, and present-moment awareness. Psychoeducation 
primarily provided health education.  Support based treatments were focused on creating a supportive environment by providing emotional or 
social support. Peer-led treatments included any treatment that was delivered by non-professional peers. Other treatments did not fit a defined 
category or combined different approaches without emphasizing any one. 
One-way ANOVAs were used to compare trial quality between these categories. Total POMRF scores and the two subscales scores 
distinguishing generic and psychotherapy design elements were evaluated. Post hoc Tukey HSD tests followed significant effects to identify 
which treatment types differed. 
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Aim 5: Quality trends over time 
Spearman correlation was calculated for year of study publication with total POMRF scores and the two subscale scores distinguishing generic 
and psychotherapy design elements. 
RESULTS 
The search retrieved 2,081 citations (Figure 1); 18 more were identified through hand searching. After removal of duplicates, 1,412 remained for 
screening based on title and abstract. Of these, 1,169 clearly did not meet the inclusion criteria. The full text articles of the remaining 252 
citations were retrieved and assessed. Ninety-one articles published from 1980 through October 2016 were eligible and included. A complete list 
of references of the included RCTs can be found in the Appendix online. 
Table 2 summarises trial characteristics. Most trials exclusively included non-metastatic BCa patients and were conducted in the United States. 
The treatment approach used most frequently was CBT and most treatments were delivered in group format. Appendix Table A3 (see online) 
provides a complete description of each trials’ characteristics. 
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Figure 1 
 
 
[Figure 1: PRISMA flow chart showing trial identification and selection] 
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Table 2 
    Treatment format  Treatment type 
 
Total sample 
 
Individual 
 
Group 
 
Couples 
 
CBT 
 
Mindfulness 
 
Psychoedu 
 
Support 
 
Peer-led 
 
Other 
 
(n=91) 
 
(n=37) 
 
(n=48) 
 
(n=6) 
 
(n=40) 
 
(n=5) 
 
(n=6) 
 
(n=21) 
 
(n=6) 
 
(n=13) 
Variable N %  N %  N %  N %  N %  N %  N %  N %  N %  N % 
Population                              
Patients                              
Total No. of 
patients 
13,553   5,553   7,334   666   4,809   922   1,102   3913   1234   1573  
Mean sample 
size per study 
149   150   153   111   120   184   184   186   205   121  
Median sample 
size per study 
117   120   119   46   100   172   162   152   198   87  
Minimum 
sample size 
14   25   32   14   14   71   66   46   104   40  
Maximum 
sample size 
558   558   382   302   355   366   367   558   305   382  
Mean age, 
years 
52   53   52   50   52   52   49   54   52   52  
Median age, 
years 
52   54   51   52   53   50   50   53   51   53  
Stage of disease                              
Non-metastatic 59 65%  23 62%  31 65%  5 83%  28 70%  5 100%  5 83%  11 52%  3 50%  7 54% 
Metastatic 7 8%  1 3%  6 13%     3 8%        4 19%     3 23% 
Both 15 16%  9 24%  5 10%  1 17%  6 15%        4 19%  2 33%    
Not reported 10 11%  4 11%  6 13%     3 8%     1 17%  2 10%  1 17%  3 23% 
Country                              
(continued on following page) 
 
    Treatment format  Treatment type 
 
Total sample 
 
Individual 
 
Group 
 
Couples 
 
CBT 
 
Mindfulness 
 
Psychoedu 
 
Support 
 
Peer-led 
 
Other 
 
(n=91) 
 
(n=37) 
 
(n=48) 
 
(n=6) 
 
(n=40) 
 
(n=5) 
 
(n=6) 
 
(n=21) 
 
(n=6) 
 
(n=13) 
Variable N %   N %   N %   N %   N %   N %   N %   N %  N %  N % 
USA 45 49%  20 54%  20 42%  5 83%  21 53%  3 60%  3 50%  10 48%  5 83%  3 23% 
Canada 10 11%  4 11%  6 13%     6 15%     1 17%  2 10%     1 8% 
Australia 7 8%  2 5%  5 10%     3 8%     1 17%  2 10%     1 8% 
UK 4 4%  3 8%  1 2%        1 20%     3 14%       
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Sweden 4 4%  2 5%  2 4%     2 5%        1 5%     1 8% 
Other 21 23%  5 14%  13 27%  1 17%  8 20%  1 20%  1 17%  3 14%  1 17%  7 54% 
 China (2), 
Croatia (1), 
Denmark (2), 
France (2), 
Germany (1), 
Greece (2), 
Holland (1), Iran 
(2), Ireland (1), 
Israel (1), Italy 
(1), Japan (2), 
Korea (1), 
Norway (1), 
Romania (1) 
 Croatia (1), 
Germany (1), 
Italy (1), 
Korea (1), 
Romania (1), 
Greece (1) 
 China (2), 
Denmark (2), 
France (2), 
Holland (1), 
Iran (1), 
Ireland (2), 
Israel (1), 
Japan (2), 
Norway (1) 
 Greece (1)  China (1), 
Croatia (1), 
Denmark (1), 
France (1), 
Iran (1), 
Ireland (1), 
Israel (1), 
Italy (1) 
 Denmark (1)  Norway (1)  China (1), 
Japan (1), 
Romania (1) 
 Korea (1)  France (1), 
Germany (1), 
Greece (2), 
Holland (1), 
Iran (1), 
Japan (1),  
 
 
 
 
                             
Exclusively 
distressed patients 
 
                             
Yes 12 13%  7 19%  5 10%        8 20%        1 5%  1 17%  2 15% 
No 
 
79 87%  29 81%  43 90%  6 100%  32 80%  5 100%  6 100%  20 95%  5 83%  11 85% 
Outcomes 
measures* 
                             
Anxiety  47 52%  22 60%  22 46%  3 50%  24 60%  3 60%  3 50%  9 43%  2 33%  6 46% 
Depression 60 66%  29 78%  27 56%  4 67%  26 65%  4 80%  4 67%  12 57%  5 83%  9 69% 
Mood/ global 
distress 
 
44 48%  10 27%  30 63%  4 67%  21 53%  2 40%  3 50%  10 48%  2 33%  6 46% 
Treatment   
(active treatment) 
                             
No. of sessions                              
Mean 8   7   9   6   9   8   5   7   7   9  
(continued on following page) 
 
    Treatment format  Treatment type 
 
Total sample 
 
Individual 
 
Group 
 
Couples 
 
CBT 
 
Mindfulness 
 
Psychoedu 
 
Support 
 
Peer-led 
 
Other 
 
(n=91) 
 
(n=37) 
 
(n=48) 
 
(n=6) 
 
(n=40) 
 
(n=5) 
 
(n=6) 
 
(n=21) 
 
(n=6) 
 
(n=13) 
Variable N %   N %   N %   N %   N %   N %   N %   N %  N %  N % 
Median 8   6   9   6                    
Minimum 1   1   1   4   1   6   3   1   3   2  
Maximum 25   25   23   8   23   11   6   16   9   25  
Variable No. of 
sessions (trials) 
9   4   5      2         5   2     
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
Not reported 
(trials) 
3   3         2         1        
Length of 
sessions (hours) 
                             
Mean 1.5   0.75   1.75   0.75   1.5   2   1.5   1.25   1.25   1.5  
Median 1.5   0.75   2   1.5      2              
Minimum 0.25   0.25   1   0.5   0.5   2   0.25   0.5   1   0.5  
Maximum 3   1.5   3   1.5   3   2   2.5   2   1.5   2.5  
Variable no of 
sessions (trials) 
12   6   6      4   3      3   2     
Not reported 
(trials) 
14   8   4   2            3   1   4  
Treatment type                              
CBT 40 44%  14 38%  22 46%  4 67%                   
Mindfulness 5 5%     5 10%                      
Psychodu 6 7%  2 5%  4 8%                      
Support 21 23%  11 30%  9 19%  1 17%                   
Peer-led 6 7%  5 14%  1 2%                      
Other 13 14%  5 14%  7 15%  1 17%                   
Treatment Format 
 
                             
Individual 37 41%           14 35%     2 33%  11 52%  5 83%  5 39% 
Group 48 53%           22 55%  5 100%  4 67%  9 43%  1 17%  7 54% 
Couples 6 7%           4 10%        1 5%     1 8% 
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[Table 2. Descriptive summary of included studies by treatment type and format. 
Abbreviations: No., number; CBT, cognitive behavioural therapy; Psychoedu, 
psychoeducation 
Notes: * Because several trials used multiple outcome measures, the number of trials 
presented for the type of outcome measure exceeds the total number of trials]  
Aim 1: Overall quality of trials  
The mean total quality score on the POMRF was 13.3 out of 38 with median 13 and IQR 6 
(i.e. 35% of the maximum possible score; median 34%, IQR 16%). Only 12 trials (13%) 
reached the criterion of 19, indicating that 79 trials (87%) were of inadequate quality. The 
mean total quality of “generic design elements” was 10.5 out of 26 with median 11 and IQR 
3 (i.e. 40% of the maximum possible score; median 42%, IQR 12%), while the mean total 
quality of “psychotherapy-specific design elements” was 2.8 out of 12 with median 2 and 
IQR 3 (i.e. 23% of the maximum possible score; median 17%, IQR 25%). In general, 
therefore, quality was poor, particularly for design elements specific to psychotherapy trials.  
Aim 2: Quality of specific design elements 
Appendix Table A4 (see online) displays the individual item quality scores for each trial. 
Four generic design elements were particularly poorly implemented: representativeness of the 
sample (item 3), use of blind evaluators (item 7), control of concomitant treatments (item 18), 
and clinical significance (item 21). These are evaluated in detail below, followed by the 
elements specific to psychotherapy trials.  
Generic design elements 
Representativeness of the sample 
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Of the 74 trials in which emotional distress was the primary outcome, only 11 (15%) 
specified as an inclusion criterion that participants were distressed. Two of these, however, 
excluded participants with clinical levels of anxiety or depression. Of the 63 trials not 
specifying distress as an inclusion criterion, two excluded participants with clinical levels of 
emotional distress and two excluded participants with prior history of psychiatric treatment  
Of the 17 trials in which emotional distress was the secondary outcome, only three (18%) 
specified that to be included participants must be experiencing the specific difficulty that the 
primary outcome measured; for example, requiring evidence of insomnia for inclusion in a 
trial in which the primary outcome was insomnia. 
Use of blind evaluators 
Only 16% of trials (n=14) reported using blind assessors, but none of these described 
ensuring that the assessor was unaware of the treatment condition. 
Control of concomitant treatments 
Only nine trials (10%) described controlling for concomitant treatments. Of these, two 
ensured that patients received no additional treatment (psychological or pharmacological); 
four excluded patients receiving additional psychological treatment (but not those receiving 
pharmacological treatment); the remaining three included patients taking anxiolytic or 
antidepressant medication provided the dose was stable. 
Clinical significance 
Only 10 trials (11%) reported the clinical significance of treatment effects. However, all 10 
used a different operational definition of clinical significance preventing assessment of the 
absolute efficacy across different treatments and trials.  
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Psychotherapy-specific design elements 
Manualised treatment 
Only 46 trials (51%) used a manual to standardise treatment. Of these, 19 referenced a 
published manual; six referred to an unpublished manual available on request; and 21 
referred to a “manual” or a “manualised treatment” without information on how to obtain it. 
An additional eight trials were ambiguous about whether a manual existed, for example 
reporting that treatment was “based on” or “modelled after” a specific manualised treatment.  
Therapist training  
Only 29 trials (32%) included therapists qualified to deliver psychotherapy, for example 
stating that therapists were “clinical psychologists”. Only seven of these (8% of trials) used 
therapists with specific training in the treatment being investigated. An additional 29 trials 
(32%) used therapists with training in the treatment being investigated, but these therapists 
either had little experience in psychotherapy, for example being “master’s level registered 
nurse therapists”, or their clinical background was not reported. Of the remaining trials, 14 
used therapists with little experience and without training in the treatment being evaluated; in 
nine it was merely stated that therapists were “trained” or “experienced”; and 10 provided no 
information about therapist training.  
Monitoring therapist adherence and competence 
Only 17 trials (15%) monitored therapist adherence and only five (4%) monitored therapist 
competence. An additional 12 reported monitoring treatment delivery but without specifying 
what aspects were monitored.   
Number of therapists 
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Most trials (67%) included more than one therapist to deliver treatment. However, of these, 
16 (18% of all trials) did not specify the number of therapists, although using the plural 
‘therapists’, and only six (7% of all trials) analysed the effect of therapist on outcome.  
Equality of therapy hours 
Eleven trials (12%) used only a wait-list control design. Of those using active treatment 
control conditions, only 19 (21% of all trials) equalized the number of treatment hours 
between conditions. Of the remaining 61 trials, 26 had more than a 20% difference in 
treatment hours between conditions, 30 did not report hours received in the control condition, 
and five did not report hours received by either condition. 
Aim 3: Quality comparison with mental health populations 
To assess the quality of RCTs in mental health populations relative to RCTs in BCa, we 
identified three meta-analyses using the POMRF addressing depression in children(39), 
obsessive compulsive disorder(28), and across several mental health populations  (e.g. anxiety, 
depression, borderline personality disorder)(30). Mean total quality scores ranged from 45 to 
52% of the maximum possible, higher than the corresponding score in the present review 
(34% of the maximum, Table 3).  Quality of generic and psychotherapy-specific design 
elements could not be compared because the mental health meta-analyses did not report 
individual item scores. 
 Number 
of RCTs 
included 
Mean 
total 
score 
Maximum 
possible 
score 
Maximum 
possible 
score as a 
% 
Range of 
scores 
Range of 
scores as a 
% 
Emotional distress in BCa 91 13.3 38 35% 6-30 16-79% 
Depression in children 10 22 44 50% 8-30 18-69% 
Individuals with mental health 
conditions 
31 20.3 44 46% - - 
OCD in adults 37 23 44 52% 15-34 34-77% 
Table 3 
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[Table 3. Comparison of total quality scores on the POMRF of RCTs in this population with 
RCTs in mental health populations.  
Abbreviations: POMRF, psychotherapy outcome study methodology rating form; RCT, 
randomised controlled trial; BCa, breast cancer; OCD, obsessive compulsive disorder] 
Aim 4: Quality comparison by treatment type 
One-way ANOVAs revealed no significant difference in overall quality scores or generic 
subscale scores. A significant difference was seen for psychotherapy specific subscale scores 
(Table 4).  Post-hoc testing showed that mindfulness trials were of better quality than support, 
peer and “other” treatment trials. However, mindfulness trials still only had a mean quality 
score of 5.4 out of 12 (i.e. 45% of the maximum possible score) on this subscale.  
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Table 4 
 [Table 4. Means (SDs) and F-values for the items on the POMRF for different treatment 
types 
Abbreviations: POMRF, psychotherapy outcome study methodology rating; psychoedu, 
psychoeducation *P<0.01,  a,bMeans with different superscript differs significantly] 
Aim 5: Quality trends over time 
The overall quality score modestly improved with year of publication (rho=0.4,p<0.001) 
(Figure 2). However, the mean total quality of the 30 trials published in the last five years 
was still only 14.7 with median 14.5 and IQR 7 (i.e. 38% of the maximum possible, median 
34%, IQR 13%) and only six of these met our criterion for adequate quality. Generic design 
elements improved across publication year (rho = 0.48, p<0.001) but psychotherapy-specific 
design elements did not (rho = 0.15, p=0.15) (Figure 3). 
[Figure 2. Scatterplot of total quality scores on the POMRF by year of publication. 
Abbreviations: POMRF, psychotherapy outcome study methodology rating form] 
[Figure 3. Scatterplot of POMRF score on generic design elements and psychotherapy-
specific design elements by year of publication. Abbreviations: POMRF, psychotherapy 
outcome study methodology rating form] 
DISCUSSION 
 
CBT  
(n=40
) 
Mindfulnes
s (n=5) 
Psychoed
u (n=6) 
Suppor
t  
(n=21) 
Other  
(n=13
) 
Peer-
led  
(n=6) 
All 
trials 
(n=91
) 
F-
value 
Total quality score 
14.13 
(4.61) 
16.6 (2.7) 
13.17 
(0.75) 
12.14 
(3.86) 
12 
(3.96) 
11.66 
(3.14) 
13.27 1.78 
Subscale 1:  Generic design elements 
11.08 
(3.2) 
11.2 (1.3) 11 (1.26) 
9.67 
(2.31) 
9.85 
(2.76) 
9.83 
(2.64) 
10.49 1.05 
Subscale 2: Psychotherapy-specific design 
elements  
3.05 
(1.99) 
5.4 (2.07)a 
2.17 
(0.75) 
2.48 
(2.18)b 
2.15 
(1.77)
b 
1.83 
(1.17)
b 
2.78 
2.81
* 
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Our findings show that the methodological quality of RCTs for emotional distress in BCa is 
poor. Most RCTs were of inadequate quality and of lower quality than those in mental health. 
While quality modestly improved from 1980 to 2016, most of the more recently published 
RCTs were still poorly designed.  
Quality was particularly poor for design elements specific to psychotherapy trials. Moreover, 
while implementation of generic design elements improved over time, that of psychotherapy-
specific ones did not. Design elements specific to psychotherapy were lacking in most trials, 
thereby compromising the internal validity of such trials. Only around one in 20 monitored 
therapist competence or analysed the effect of therapist on outcome; only around one in 10 
employed therapists who were adequately trained in the treatments or monitored therapists’ 
adherence to them; only around one in five compared conditions with an equal number of 
treatment hours; and barely half used a manual to standardise treatment. The purpose of these 
design elements is to ensure that a psychological treatment is implemented correctly. Because 
none of the trials in this review adequately implemented all these elements, their findings 
provide unreliable information about the treatments the authors are claiming to evaluate. 
Although, in general, generic design elements were not as poorly conducted as those specific 
to psychotherapy trials, important ones were still neglected, thereby further compromising 
trials’ internal and external validity.  Only around one in 10 trials controlled for concomitant 
treatments, blinded assessors, specified as an inclusion criterion that participants were 
distressed, or reported the clinical significance of treatment effects.  
While all these areas represent significant deficits in the BCa literature, the latter two are 
particularly concerning. Consensus-based clinical practice guidelines specifically recommend 
the use of psychological treatments for BCa patients experiencing clinical levels of emotional 
distress(43, 44) and the standards by which a treatment is considered “evidence based” 
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recommend that trials provide an estimation of clinical significance(33, 45).  If trials do not 
target patients with emotional distress, findings cannot be generalised to the population of 
patients to whom the treatments would be offered in practice: i.e. those with clinical levels of 
emotional distress. Additionally, if trialists do not report the clinical significance of treatment 
effects, it is difficult for researchers, clinicians, service providers and policy-makers to assess 
the practical relevance of findings. Determining and applying standardised criteria for the 
clinical significance of treatment effects would advance psychotherapy outcome research in 
BCa.  The most established method for determining clinical significance(46) is the approach 
developed by Jacobson and colleagues(47, 48). There are two components to the approach, the 
first determines if the degree of change following treatment is statistically significant beyond 
the degree of change that could be an artefact of repeated measurement. The second 
determines if treated individuals are distinguishable from a representative normative 
population. To be classified as recovered, an individual must a) show a change larger than 
measurement error and b) be indistinguishable from a normative population following 
treatment. 
The overall methodological quality of trials did not differ by type of treatment. For design 
elements specific to psychotherapy trials, quality did differ by type of treatment explored, 
with mindfulness treatment trials achieving better quality scores than support, peer, and 
“other” treatment trials However, trials evaluating mindfulness-based treatments were still of 
limited quality. Many of the trials provided insufficient details about treatment methods and 
procedures. Thus, it was not possible to categorise treatments by distinct treatment 
approaches, but only by broad categories of type of treatment. This highlights the importance 
of studies clearly reporting the type of treatment used with clear and unambiguous 
descriptions of the treatments being compared.   
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Although the methodological quality of trials modestly improved over time, the majority of 
the most recent RCTs were still of inadequate quality. Thus, there is clearly substantial room 
for improvement in the conduct of RCTs in this population. 
This review has some important limitations. Our assessment of study quality was limited to 
what was included in the published reports. As most journals impose word limits, authors 
may have excluded important information. Thus, some trials may have implemented 
unreported design elements.  We also relied on summary scores to quantify the overall 
quality of trials. Summary scores can be problematic as they can mask methodological 
strengths and weaknesses of a trial. Trials that differ in the conduct of individual design 
elements may still result in the same overall score. Finally, we did not evaluate whether 
methodological quality differed amongst trials including patients at different points in the 
BCa trajectory, because many trials included patients at multiple points in the disease 
trajectory.  
In conclusion, the current view that efficacious psychological treatments exist for distress in 
BCa patients is based on poor quality RCTs. It does not follow that efficacious treatment do 
not exist, or that conclusions of previous reviews are wrong. However, with increasing 
investment in, and growing priority of, psychological treatments for emotional distress in 
BCa(10, 49), it is imperative that future psychological treatment trials are conducted with 
greater methodological rigour to make sure evidence based practice occurs in clinical 
settings. We urge researchers to ensure that the methodological issues presented in this 
review are adequately implemented in future trials. In particular, trials need to include 
participants with clinical levels of emotional distress, control for concurrent treatments and 
report the clinical significance of treatment outcomes. Trialists must also consider the 
methodological challenges specific to psychotherapy trials. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Disclaimer: The authors acknowledge no financial interest or benefit arising from the direct 
applications of their research  
Conflicts of interest: The authors have no competing interests to report 
 
REFERENCES 
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 
2016;66(1):7-30. 
2. Bouchard LC, Antoni MH, Blomberg BB, Stagl JM, Gudenkauf LM, Jutagir DR, et al. 
Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing 
Primary Treatment for Breast Cancer. Psychosomatic medicine. 2016;78(1):26-37. 
3. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in 
women with early breast cancer: five year observational cohort study. Bmj. 2005;330(7493):702. 
4. Henselmans I, Helgeson VS, Seltman H, de Vries J, Sanderman R, Ranchor AV. Identification 
and prediction of distress trajectories in the first year after a breast cancer diagnosis. Health 
Psychology. 2010;29(2):160. 
5. Spitzer R, Williams J, Gibbon M, First M. Structured Clinical Interview for DSM-III-R/DSM-IV 
Patient Edition (SCID-P). New York: New York State Psychiatr Inst. 1990. 
6. Badger TA, Braden CJ, Mishel MH, Longman A. Depression burden, psychological 
adjustment, and quality of life in women with breast cancer: patterns over time. Research in nursing 
& health. 2004;27(1):19-28. 
7. Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and 
degree of acceptance of adjuvant cytotoxic drugs. The Lancet. 2000;356(9238):1326-7. 
8. Simpson J, Carlson L, Trew M. Impact of a group psychosocial intervention on health care 
utilization by breast cancer patients. Cancer Pract. 2001;9(1):19-26. 
9. Trask PC, Paterson AG, Wang C, Hayasaka S, Milliron KJ, Blumberg LR, et al. Cancer‐specific 
worry interference in women attending a breast and ovarian cancer risk evaluation program: impact 
on emotional distress and health functioning. Psycho‐Oncology. 2001;10(5):349-60. 
10. Jassim GA, Whitford DL, Hickey A, Carter B. Psychological interventions for women with 
non‐metastatic breast cancer. The Cochrane Library. 2015. 
11. Mustafa M, Carson‐Stevens A, Gillespie D, Edwards AG. Psychological interventions for 
women with metastatic breast cancer. The Cochrane Library. 2013. 
12. Naaman SC, Radwan K, Fergusson D, Johnson S. Status of psychological trials in breast cancer 
patients: a report of three meta-analyses. Psychiatry: Interpersonal and Biological Processes. 
2009;72(1):50-69. 
13. Xiao F, Song X, Chen Q, Dai Y, Xu R, Qiu C, et al. Effectiveness of psychological interventions 
on depression in patients after breast cancer surgery: A meta-analysis of randomized controlled 
trials. Clinical breast cancer. 2017;17(3):171-9. 
14. Zhang J, Xu R, Wang B, Wang J. Effects of mindfulness-based therapy for patients with breast 
cancer: A systematic review and meta-analysis. Complementary therapies in medicine. 2016;26:1-10. 
15. Duijts SF, Faber MM, Oldenburg HS, van Beurden M, Aaronson NK. Effectiveness of 
behavioral techniques and physical exercise on psychosocial functioning and health‐related quality 
of life in breast cancer patients and survivors—a meta‐ analysis. Psycho ‐ Oncology. 
2011;20(2):115-26. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
16. Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for distress and pain in 
breast cancer patients: a meta-analysis. Journal of behavioral medicine. 2006;29(1):17-27. 
17. Zimmermann T, Heinrichs N, Baucom DH. “Does one size fit all?” moderators in psychosocial 
interventions for breast cancer patients: A meta-analysis. Annals of Behavioral Medicine. 
2007;34(3):225-39. 
18. Barth J, Munder T, Gerger H, Nüesch E, Trelle S, Znoj H, et al. Comparative efficacy of seven 
psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS 
medicine. 2013;10(5):e1001454. 
19. Bohlmeijer E, Prenger R, Taal E, Cuijpers P. The effects of mindfulness-based stress reduction 
therapy on mental health of adults with a chronic medical disease: a meta-analysis. Journal of 
psychosomatic research. 2010;68(6):539-44. 
20. Bolier L, Haverman M, Westerhof GJ, Riper H, Smit F, Bohlmeijer E. Positive psychology 
interventions: a meta-analysis of randomized controlled studies. BMC public health. 2013;13(1):119. 
21. Cuijpers P, van Straten A, Bohlmeijer E, Hollon S, Andersson G. The effects of psychotherapy 
for adult depression are overestimated: a meta-analysis of study quality and effect size. 
Psychological medicine. 2010;40(2):211-23. 
22. Huhn M, Tardy M, Spineli LM, Kissling W, Förstl H, Pitschel-Walz G, et al. Efficacy of 
pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-
analyses. JAMA psychiatry. 2014;71(6):706-15. 
23. Klein JB, Jacobs RH, Reinecke MA. Cognitive-behavioral therapy for adolescent depression: a 
meta-analytic investigation of changes in effect-size estimates. Journal of the American Academy of 
Child & Adolescent Psychiatry. 2007;46(11):1403-13. 
24. Gellatly J, Bower P, Hennessy S, Richards D, Gilbody S, Lovell K. What makes self-help 
interventions effective in the management of depressive symptoms? Meta-analysis and meta-
regression. Psychological medicine. 2007;37(9):1217-28. 
25. Frühauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions 
for sexual dysfunction: a systematic review and meta-analysis. Archives of Sexual Behavior. 
2013;42(6):915-33. 
26. Jauhar S, McKenna P, Radua J, Fung E, Salvador R, Laws K. Cognitive-behavioural therapy for 
the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential 
bias. The British Journal of Psychiatry. 2014;204(1):20-9. 
27. Gerber AJ, Kocsis JH, Milrod BL, Roose SP, Barber JP, Thase ME, et al. A Quality-Based Review 
of Randomized Controlled Trials of Psychodynamic Psychotherapy. American Journal of Psychiatry. 
2011;168(1):19-28. 
28. Öst L-G, Havnen A, Hansen B, Kvale G. Cognitive behavioral treatments of obsessive–
compulsive disorder. A systematic review and meta-analysis of studies published 1993–2014. Clinical 
psychology review. 2015;40:156-69. 
29. Thoma NC, McKay D, Gerber AJ, Milrod BL, Edwards AR, Kocsis JH. A quality-based review of 
randomized controlled trials of cognitive-behavioral therapy for depression: an assessment and 
metaregression. American Journal of Psychiatry. 2012;169(1):22-30. 
30. Johnsen TJ, Friborg O. The effects of cognitive behavioral therapy as an anti-depressive 
treatment is falling: A meta-analysis. American Psychological Association; 2015. 
31. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. 
32. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the 
quality of reports of randomized clinical trials: is blinding necessary? Controlled clinical trials. 
1996;17(1):1-12. 
33. Chambless DL, Hollon SD. Defining empirically supported therapies. Journal of consulting 
and clinical psychology. 1998;66(1):7. 
34. Kazdin AE. Research Design in Clinical Psychology: TPB; 2007. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
35. Yeaton WH, Sechrest L. Critical dimensions in the choice and maintenance of successful 
treatments: Strength, integrity, and effectiveness. Journal of consulting and clinical psychology. 
1981;49(2):156. 
36. Forsberg S, Fitzpatrick KK, Darcy A, Aspen V, Accurso EC, Bryson SW, et al. Development and 
evaluation of a treatment fidelity instrument for family‐based treatment of adolescent anorexia 
nervosa. International Journal of Eating Disorders. 2015;48(1):91-9. 
37. Roth AD, Pilling S, Turner J. Therapist training and supervision in clinical trials: Implications 
for clinical practice. Behavioural and Cognitive Psychotherapy. 2010;38(3):291-302. 
38. Öst L-G. Efficacy of the third wave of behavioral therapies: A systematic review and meta-
analysis. Behaviour research and therapy. 2008;46(3):296-321. 
39. Arnberg A, Öst L-G. CBT for children with depressive symptoms: a meta-analysis. Cognitive 
behaviour therapy. 2014;43(4):275-88. 
40. Ost LG. The efficacy of Acceptance and Commitment Therapy: an updated systematic review 
and meta-analysis. Behav Res Ther. 2014;61:105-21. 
41. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA 
statement for reporting systematic reviews and meta-analyses of studies that evaluate health care 
interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. 
42. Kocsis JH, Gerber AJ, Milrod B, Roose SP, Barber J, Thase ME, et al. A new scale for assessing 
the quality of randomized clinical trials of psychotherapy. Comprehensive psychiatry. 
2010;51(3):319-24. 
43. NCCN practice guidelines for the management of psychosocial distress. National 
Comprehensive Cancer Network. Oncology (Williston Park, NY). 1999;13(5A):113-47. 
44. Coleman N, Hession N, Connolly A. Psycho-oncology best practice guidelines and a service 
perspective: Conceptualising the fit and towards bridging the gap. The Irish Journal of Psychology. 
2011;32(1-2):72-89. 
45. Tolin DF, McKay D, Forman EM, Klonsky ED, Thombs BD. Empirically supported treatment: 
Recommendations for a new model. Clinical Psychology: Science and Practice. 2015;22(4):317-38. 
46. Ronk FR, Hooke GR, Page AC. Validity of clinically significant change classifications yielded by 
Jacobson-Truax and Hageman-Arrindell methods. BMC psychiatry. 2016;16(1):187. 
47. Jacobson NS, Follette WC, Revenstorf D. Psychotherapy outcome research: Methods for 
reporting variability and evaluating clinical significance. Behavior therapy. 1984;15(4):336-52. 
48. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful 
change in psychotherapy research. Journal of consulting and clinical psychology. 1991;59(1):12. 
49. Council NR. Meeting psychosocial needs of women with breast cancer: National Academies 
Press; 2004. 
  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
sDeclarations of interest: None. The authors have no competing interests to report 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Fig 2 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Fig 3 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Highlights 
 Anxiety and depression are common in Breast Cancer (BCa) patients  
 Psychological treatment trials for emotional distress in BCa are of poor quality 
 Components specific to psychological treatment trials are of poorest quality 
 The overall methodological quality of trials does not differ by treatment type 
 Methodological quality of psychological treatment trials is improving 
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